We retrospectively analyzed the association between anti-host isohemagglutinin (IH) production and the development of acute GVHD. Of 189 patients who received minor or major/minor ABO-incompatible hematopoietic SCT (HSCT) at our hospital, 36 patients (19%) showed IH production. IH was detected before the onset of acute GVHD in 10, around the same time in 8, and after the onset of acute GVHD in 17 patients. The cumulative incidence of grade II --IV acute GVHD was significantly higher in the IH þ group compared with the IHÀ group (Po0.0001). The higher risk of acute GVHD that was associated with IH production occurred irrespective of human leukocyte Ag compatibility and donor type. Furthermore, the incidence of acute GVHD in the IHÀ group was comparable to that seen in major ABO-incompatible or -compatible HSCT. Our findings not only showed a strong association between IH production and acute GVHD development, but also suggested that IH production might be a useful predictor of subsequent acute GVHD after ABO-incompatible HSCT.
INTRODUCTION
GVHD is a major adverse event of allogeneic hematopoietic SCT (HSCT). HLA disparity is considered to be the major predictor of the development of GVHD. 1 Other suggested predictive factors include age, stem cell source, patient --donor sex mismatch, and mismatched mHAs.
2 --4 ABO incompatibility has generally not been considered to be a risk factor for acute GVHD. 5 --8 However, in patients who received BMT or PBSC transplantation (PBSCT) at our hospital, the cumulative incidence of grade II --IV acute GVHD was higher in the minor or major/minor ABO-mismatched patients compared with the other patient groups (45% vs 34%, P ¼ 0.0044; Figure 1 ). This prompted us to investigate additional factors that could affect the onset of acute GVHD in such types of patients. In yet another study, 9 it was reported that patients with acute GVHD tended to have a higher incidence of increased donor-derived isohemagglutinin (IH). Therefore, we decided to retrospectively analyze the association between the onset of acute GVHD and IH production.
PATIENTS AND METHODS

Patient selection
Between 1993 and 2010, there were 752 patients who received their first allogeneic HSCT at our hospital. Nine patients were excluded from our analysis because of a lack of data, and 74 patients who underwent cord blood SCT (CBT) were also excluded. Out of the remaining 669 patients in this study cohort, only one patient received unrelated PBSCT, with the rest receiving related/ unrelated BMT or related PBSCT. None of them received T-cell depleted HSCT. Out of this group, a total of 189 patients received minor or major/minor ABO-incompatible HSCT. Thus, we retrospectively reviewed the charts for these particular patients and investigated whether there was a correlation between IH production and the development of acute GVHD. This study was approved by the institutional ethics committee with a waiver of written informed consent because it was a retrospective study.
Monitoring and determination of IH titer, BM manipulation, and GVHD prophylaxis Anti-host IH levels were evaluated at least weekly during the first month after HSCT, with the evaluations then repeated monthly until the blood type completely changed to the donor type. IgM IH titers were determined by incubating a suspension of 50 mL of standard type A and B RBCs (Affirmagen, Ortho Clinical Diagnostics, Tokyo, Japan) with 100 mL of twofold serial dilution of the patient's plasma at room temperature followed by centrifugation. For IgG IH, the patient's plasma was treated with an equal volume of 2-ME at 37 1C for 2 h, and dialyzed with saline. A suspension of 50 mL of standard type A and B RBCs and 2 drops of PEG were added to 100 mL of twofold serial dilution of 2ME-treated plasma and incubated at 37 1C for 15 min. After adding two drops of rabbit anti-human IgG serum (Ortho Clinical Diagnostics), the samples were centrifuged, and IgG IH titers were determined. The IH titers were measured by professional technicians in the transfusion and cell therapy division in our hospital.
In cases of ABO major or major/minor mismatched HSCT, for RBC depletion, mononuclear cells were isolated from BM using the COBE Spectra apheresis system (CaridianBCT, Lakewood, CO, USA). In cases of ABO minor mismatched HSCT, for the removal of anti-host ABO Ab, BM was centrifuged and the plasma removed. After that, the marrow cells were resuspended with heparinized saline (10 U/mL).
Most patients received G-CSF beginning at 5 days after the HSCT, and continued until the neutrophil count was 4500. Prophylaxis for acute GVHD consisted of a short course of MTX and CsA/tacrolimus (FK). FK was used in cases of either unrelated or HLA-mismatched HSCT. CsA/FK was administered from day À1, initially as a continuous infusion, at doses of 3 mg/kg per day for CsA and 0.02 --0.03 mg/kg per day for FK. The doses were adjusted to maintain levels at 200 --300 ng/mL for CsA and 10 --15 ng/mL for FK, respectively. Acute GVHD cases that developed within 100 days after HSCT were diagnosed and graded according to the previously established criteria. 10 
Statistical analysis
Continuous baseline characteristics were compared using Student's t-test (patient age) or the Mann --Whitney test (other variables). OS was calculated from the date of the first transplantation to the final followup or death. Disease-free survival (DFS) was calculated from the first transplantation to the last follow-up or the date when the underlying diseases relapsed. Time to engraftment was defined as the first day of 3 consecutive days with neutrophil count above 500/mL. Categorical characteristics were compared using the w 2 test or Fisher's exact test. The values for the incidence of acute GVHD, OS and DFS were estimated using the Kaplan --Meier method and then compared using the log-rank test. All statistical tests were two-sided, with Po0.05 considered statistically significant. All data were analyzed using SPSS II software (IBM SPSS, Chicago, IL, USA).
RESULTS
Patient characteristics
This study analyzed 115 males and 74 females with a median age of 38 years (range: 16--69 years). The median follow-up period was 728 days after HSCT (range: 2--6493 days). Out of this group, there were 36 (19.0%) patients who exhibited anti-host IgG or IgM IH (Table 1) . Although patients who received CBT were excluded from this study, none of them showed IH production (data not shown). HLAmismatched HSCT was significantly higher in the IH positive (IH þ ) group (P ¼ 0.001). Of 43 HLA mismatched patients, most patients (n ¼ 40) received DR locus mismatched HSCT, 2 received A locus mismatched, and 1 received B locus mismatched HSCT, respectively. None of them received X2 loci mismatched HSCT. With respect to donor type, whereas unrelated HSCT was more frequent in the IH þ group, this value did not reach statistical significance (P ¼ 0.084). IH þ and IHÀ patients did not differ significantly in terms of age (both donor and recipient), sex, ABO incompatibility, patient--donor sex matching, conditioning regimen, donor source or donor type.
The incidence of acute GVHD and clinical outcomes related to IH production Detection of IH occurred before the onset of acute GVHD (all grades) in 10 patients, around the same time (±1 day) in 8 Figure 1 . The cumulative incidence of grade II--IV acute GVHD related to ABO compatibility. The incidence of grade II--IV acute GVHD was higher in minor and major/minor ABO-incompatible HSCT than in ABO-compatible and major ABO-incompatible HSCT (45% vs 34%). patients, and after the onset of acute GVHD in 17 patients. IH production began at a median of 13 days after HSCT (9 to 47 days). The cumulative incidence of grade II --IV acute GVHD was significantly higher in the IH þ group compared with the IHÀ group (83% vs 36%, Po0.0001) (Figure 2 ). The use of systemic steroids was more frequent in the IH þ group (Table 1) . There was also a significantly earlier time of onset of grade II --IV acute GVHD in the IH þ group (median: 9 days in the IH þ group vs 16.5 days in the IHÀ group, P ¼ 0.001). Although all patients who developed grade IV acute GVHD had an IH titer X4, the IH titer did not show any statistical difference in the severity of acute GVHD (P ¼ 0.053) ( Table 2 ). In the subgroup analyses, IH production was also associated with a higher risk of grade II --IV acute GVHD in related HLA-matched, unrelated HLA-matched, and unrelated HLA-mismatched groups (Figures 3a --c) . We could not evaluate the correlation between IH production and the incidence of acute GVHD in the related HLA-mismatched group because only two patients belonged to this group. With respect to underlying disease, the incidence of grade II --IV acute GVHD was also significantly higher in the IH þ group in AML, CML, ALL, aplastic anemia and myelofibrosis (Figures 4a, b, d , e, respectively), whereas patients with myelodysplastic syndrome (MDS) did not show a significant difference (P ¼ 0.4175) (Figure 4c ). Furthermore, the cumulative incidence of grade II --IV acute GVHD in the IHÀ group was comparable to that seen in the major ABO-incompatible or -compatible groups (P ¼ 0.6563) ( Figure 5 ). No statistical differences were observed for the time to engraftment (median: 17 days after HSCT in IH þ vs 19 days in IHÀ, P ¼ 0.097) ( Table 1) or OS (48.7% in IH þ vs 43.9% in IHÀ at 5 years, P ¼ 0.5528) (Figure 6a ). Although the IH þ patients showed better DFS than the IHÀ patients, this difference did not reach statistical significance (79.6% in IH þ vs 64.5% in IHÀ at 5 years, P ¼ 0.1790) (Figure 6b) .
DISCUSSION
In the current study, we retrospectively analyzed the association between anti-host IH production and the development of acute GVHD. The incidence of grade II --IV acute GVHD was higher in the IH þ group irrespective of donor type, HLA disparity, or underlying diseases other than MDS (Figures 3 and 4) . On the other hand, the incidence of acute GVHD in the IHÀ group was compatible with that of the ABO-compatible and major mismatched groups, in which anti-host IH is never produced ( Figure 5) . Thus, the present findings indicated that anti-host IH production was strongly associated with the development of acute GVHD.
The small sizes of the patient groups, especially of the IH þ group, is one of the limitations of our study. We could not evaluate the incidence of acute GVHD in the related HLA-matched group because of the small patient number. In patients with MDS, there were only 9 and 8 patients in the IH þ and IHÀ groups, respectively. Regarding the IH titer, it should be noted that all patients who developed grade IV acute GVHD showed an IH titer X4. Our study, however, did not show a significant correlation between IH titer and the severity of acute GVHD. The small patient number may also militate against these outcomes.
Despite a strong difference in the cumulative incidence of acute GVHD between the IH þ and IHÀ groups, the OS and DFS did not differ significantly. The reason for these results is unclear, but 
Abbreviation: IH ¼ isohemagglutinin. better DFS in the IH þ group might be countered by a high incidence of acute GVHD. Although donor T cells are known to have a crucial role in the development of acute GVHD, the role of donor B cells remains controversial at the present time. A previous study 11 demonstrated that a higher number of infused B lineage-specific progenitor cells was inversely associated with the development of acute GVHD. On the other hand, one other study 12 has reported that B-cell depletion caused a reduced incidence of acute GVHD in a mouse model, whereas a different study demonstrated there was a correlation between the dose of CD20 positive cells and acute GVHD. 13 In our study, we excluded cases of CBT because of the unique immunological tolerance that was present. It should be noted, however, that none of the patients who received CBT showed any IH production. In a subsequent B-cell subset analysis, it was shown that B cells in cord blood had a high proportion of immature transitional B cells, along with insufficient memory B cells and CD40 mediated signals. As a result, this led to a defect in the developmental and functional recovery of the B cells after CBT. 14 Although ABO incompatibility is not generally considered to be a risk factor for acute GVHD, other studies have shown that minor or major/minor ABO-incompatible HSCT is also associated with a Figure 6 . Overall survival and disease-free survival related to IH production. No statistical differences were observed for both OS (48.7% in IH þ vs 43.9% in IHÀ at 5 years) and DFS (79.6% in IH þ vs 64.5% in IHÀ at 5 years).
higher risk of acute GVHD. 15 --18 The interaction between anti-A/B Ab and A/B Ag, which is also expressed on other tissues, has been postulated to induce endothelial injury and lead to the development of acute GVHD. 17 However, half of the patients in our study showed IH production after the onset of acute GVHD. Thus, as opposed to being a trigger of acute GVHD, the appearance of IH may simply reflect the B-cell activity. Therefore, the interaction between the host A/B Ag and the donor B cells could potentially induce host B-cell activation, resulting in the development of acute GVHD and IH production.
Because B cell activity was not studied in our investigation, we cannot demonstrate a direct association between B cell activity and the development of acute GVHD. However, when taken together, our current findings indicate there is a correlation between B cell activity and the onset of acute GVHD. In addition, our results also suggest that IH production might very well be a useful predictor for acute GVHD.
